Circumventing the requirement of binding saturation for receptor quantification using interaction kinetic extrapolation

Nuclear Medicine Communications

Volumn 32, Issue 9, 2011, Pages 863-867

  Barta, Pavel ^a,c   Björkelund, Hanna ^a,b   Andersson, Karl ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Ridgeview Instruments AB   (Sweden)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Kinetics; ligand receptor interaction; receptor quantification

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IODINE 125; LIGAND; REAGENT; TRASTUZUMAB; TUMOR MARKER;

ACCURACY; ARTICLE; ASSAY; BINDING SATURATION ASSAY; CANCER CELL CULTURE; CELL COUNT; CLINICAL ASSESSMENT; DIAGNOSTIC IMAGING; EVALUATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTERACTION KINETIC EXTRAPOLATION; ISOTOPE LABELING; KINETICS; LIGAND BINDING; MEASUREMENT; NUMBER OF RECEPTORS PER CELL; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HUMANS; KINETICS; MODELS, BIOLOGICAL; PROTEIN BINDING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 80051789752     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283483e1c     Document Type: Article

References (10)

1. Hulme EC, Trevethick MA. Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacology 2010;161:1219-1237. doi: 10.1111/j.1476-5381.2009.00604.x.
2. Nestor M. Effect of cetuximab treatment in squamous cell carcinomas. Tumor Biol 2010;31:141-147. doi 10.1007/s13277-010-0018-8.
3. Brotherick I, Lennard TWJ, Wilkinson SE, Cook S, Angus B, Shenton BK. Flow cytometric method for the measurement of epidermal growth factor receptor and comparison with the radio-ligand binding assay. Cytometry 1994;16:262-269.
4. Hanna W. Testing for HER2 status. Oncology 2001;61:22-30. (Pubitemid 33033421)
5. Björke H, Andersson K. Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Applied Radiat Isotopes 2005;64:32-37. (Pubitemid 41550168)
6. Greenwood FC, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114.
7. Björkelund H, Gedda L, Andersson K. Avoiding false negative results in specificity analysis of protein-protein interactions. J Mol Recognit 2011;24:81-89. doi:10.1002/jmr.1026.
8. Adamson ED, Rees AR. Epidermal growth factor receptors. Mol Cellular Biochem 1981;34:129-152. (Pubitemid 11140190)
9. Andersson K, Björkelund H, Malmqvist M. Antibody-antigen interactions: what is the required time to equilibrium? Available from Nature Procedings < http://hdl.handle.net/10101/npre.2010.5218.1 >. 2010.
10. Persson MI, Gedda L, Jensen HJ, Lundqvist H, Malmström PU, Tolmachev V. Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours. Oncol Rep 2006;15:673-680.